Abstract
Background:
Human papillomavirus (HPV)-related squamous cell cancer of the head and neck (SCCHN) has emerged as a distinct clinical entity. The expression of p16 protein can be used as a surrogate for HPV status.
Methods:
p16 immunohistochemistry (IHC) was assessed in archival paraffin-embedded material for 55 patients with locally advanced SCCHN treated with a uniform regimen of cisplatin and radiation. HPV status was assessed by colorimetric in situ hybridization (CISH) and polymerase chain reaction (PCR).
Results:
Compared with p16- and HPV-negative patients, the p16- and HPV-positive patients had improved overall survival, disease-free survival, and locoregional recurrence rates.
Conclusions:
p16 IHC may serve as a useful surrogate and prognostic marker for patients with HPV-related SCCHN treated with cisplatin and radiation.
Copyright © 2010 Wiley Periodicals, Inc.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alphapapillomavirus / isolation & purification
-
Antineoplastic Agents / therapeutic use*
-
Biomarkers, Tumor / analysis*
-
Biomarkers, Tumor / genetics
-
Carcinoma / chemistry
-
Carcinoma / drug therapy
-
Carcinoma / pathology
-
Carcinoma / radiotherapy
-
Carcinoma / virology
-
Carcinoma, Squamous Cell
-
Chemotherapy, Adjuvant
-
Cisplatin / therapeutic use*
-
Cyclin-Dependent Kinase Inhibitor p16 / analysis*
-
Cyclin-Dependent Kinase Inhibitor p16 / genetics
-
Female
-
Head and Neck Neoplasms / chemistry
-
Head and Neck Neoplasms / drug therapy
-
Head and Neck Neoplasms / pathology
-
Head and Neck Neoplasms / radiotherapy
-
Head and Neck Neoplasms / virology
-
Humans
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Neoplasms, Squamous Cell / chemistry
-
Neoplasms, Squamous Cell / drug therapy
-
Neoplasms, Squamous Cell / pathology
-
Neoplasms, Squamous Cell / radiotherapy
-
Neoplasms, Squamous Cell / virology
-
Predictive Value of Tests
-
Prognosis
-
Radiotherapy, Adjuvant
-
Retrospective Studies
-
Squamous Cell Carcinoma of Head and Neck
-
Survival Analysis
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Cyclin-Dependent Kinase Inhibitor p16
-
Cisplatin